This compares to total revenue of $64.0 million in the third quarter of 2011, made up of product revenue of $57.0 million and service and other revenue of $7.0 million. Product income included consumable revenue of $52.9 million and instrument revenue of $4.1 million in the third quarter of 2011. For the third quarter of 2012, price of product sales, including eBioscience, was $34.0 million, as compared to $24.6 million in the same amount of 2011. Product gross margin was 53 percent, when compared with 57 percent in the same period of 2011, the lower is due primarily to the amortization of the step-up in inventory fair value of $4.5 million. Excluding the inventory step-up amortization, product gross margin for the third quarter of 2012 was 57 percent.Medicare beneficiaries who join the plan and fill up their prescriptions at a CVS/pharmacy pays a $3 copayment for chosen generic prescriptions and save $10 on copayments for non-preferred generic and chosen brand prescriptions. We are committed to providing value to our Medicare beneficiaries, which new plan isn’t just affordable, it does increase our members’ usage of one of the premier pharmacy chains in the usa, said John Chomeau, head of Aetna Medicare. With 75 percent of the US population in the markets where CVS/pharmacy operates living within 3 kilometers of a CVS drugstore, Medicare beneficiaries shall have convenient usage of the prescription drugs they need through this plan.